Investigating how lipid kinases affect immune cell function and metabolism
Chemical proteomic investigation of lipid kinase specificity and druggability
This study is looking at how certain enzymes called diacylglycerol kinases (DGKs) affect the immune system, with the goal of finding new ways to boost immune responses in cancer treatment by blocking specific types of these enzymes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-11021100 on NIH RePORTER |
What this research studies
This research focuses on diacylglycerol kinases (DGKs), which are enzymes that play a crucial role in cellular signaling by converting diacylglycerol into phosphatidic acid. By understanding how these enzymes work, particularly their active sites and how they interact with other molecules, the research aims to identify potential therapeutic targets for enhancing immune responses, especially in cancer treatment. The study will involve both laboratory experiments and analysis of genetic and clinical data to explore how inhibiting specific DGK isoforms can improve the activity of immune cells in tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer who may benefit from therapies aimed at boosting immune cell activity.
Not a fit: Patients with non-cancerous conditions or those not experiencing immune suppression may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the immune system's ability to fight cancer.
How similar studies have performed: Previous research has shown promise in targeting lipid kinases for therapeutic purposes, indicating potential success for this approach.
Where this research is happening
Austin, United States
- University of Texas at Austin — Austin, United States (Active)
Researchers
- Principal investigator: Hsu, Ku-Lung — University of Texas at Austin
- Study coordinator: Hsu, Ku-Lung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.